Glycogen synthase kinase-3 (GSK-3) inhibitor
Home > PRODUCTS > Biochemicals > Glycogen synthase kinase-3 (GSK-3) inhibitor

Academic Discounts 2019

Newsletter Subscription

Stay updated with our new products and services. You can unsubscribe at any time.

Glycogen synthase kinase-3 (GSK-3) inhibitor

3-[[6-(3-aminophenyl)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]-phenol (TWS119)
• TWS119 is a 4,6 disubstituted pyrrolopyrimidine that potently inhibits GSK3β with an IC50 value of 30 nM. At 400 nM, TWS119 induces neurogenesis in murine embryonic stem cells making it a useful tool to regulate stem cell self-renewal and differentiation

OTAVAchemicals Catalogue Number: 7070707013
CAS Registry Number: 601514-19-6
Purity: 97%+ (HPLC)

Ref. 1: Dessalew et al. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening. Chemical Biology & Drug Design (2006), 68, 154-165

Abstract: To investigate the identification of new potential glycogen synthase kinase-3 inhibitors, a pharmacophore mapping study was carried out using a set of 21 structurally diverse glycogen synthase kinase-3 inhibitors. The best hypothesis was used to screen electronically the NCI2000 database. The hits obtained were docked into glycogen synthase kinase-3β active site. A total of five novel potential leads were proposed after: (i) visual examination of how well they dock into the glycogen synthase kinase-3β-binding site, (ii) comparative analysis of their FlexX, G-Score, PMF-Score, ChemScore and D-Scores values, (iii) comparison of their best fit value with the known inhibitors and (iv) examination of the how the hits retain interactions with the important amino acid residues of glycogen synthase kinase-3β-binding site.


Ref. 2: Ding et al. Synthetic small molecules that control stem cell fate. Proceedings of the National Academy of Sciences of the United States of America (2003), 100, 7632-7637

Abstract: A high-throughput phenotypic cell-based screen of kinase-directed combinatorial libraries led to the discovery of TWS119, a 4,6-disubstituted pyrrolopyrimidine that can induce neurogenesis in murine ESCs. The target of TWS119 was shown to be glycogen synthase kinase-3β (GSK-3β) by both affinity-based and biochemical methods. This study provides evidence that GSK-3β is involved in the induction of mammalian neurogenesis in ESCs. This and such other molecules are likely to provide insights into the molecular mechanisms that control stem cell fate and may ultimately be useful to in vivo stem cell biology and therapy.